Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

Published:2015-07-21 Issue:2 Volume:51 Page:162-172
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Namisaki Tadashi,Noguchi Ryuichi,Moriya Kei,Kitade Mitsuteru,Aihara Yosuke,Douhara Akitoshi,Nishimura Norihisa,Takeda Kosuke,Okura Yasushi,Kawaratani Hideto,Takaya Hiroaki,Seki Kenichiro,Yoshiji Hitoshi

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-015-1104-x.pdf

Reference36 articles.

1. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–8.

2. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537–43.

3. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–9.

4. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011–9.

5. Douhara A, Moriya K, Yoshiji H, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11:1693–700.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD);Tissue Barriers;2023-12-05

2. Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study;Scientific Reports;2022-09-16

3. The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis;Frontiers in Cellular and Infection Microbiology;2022-09-15

4. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis;Indian Journal of Gastroenterology;2022-03-12

5. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2022-03